Field Trip Health - CEO, Joseph del Moral.
CEO, Joseph del Moral.
Source: Field Trip Health.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Field Trip Health (FTRP) has obtained conditional approval to list on the NASDAQ Global Select Market under the symbol FTRP
  • Field Trip’s shares will continue to trade on the TSX but will be removed from the U.S. OTCQX upon the NASDAQ listing
  • The company expects to satisfy all NASDAQ requirements and will issue a statement once a trading date has been confirmed
  • Field Trip is focused on the development and delivery of psychedelic therapies
  • Field Trip Health (FTRP) is unchanged at $7.43 per share

Field Trip Health (FTRP) has obtained conditional approval to list on the NASDAQ Global Select Market under the symbol FTRP.

The company’s common stock will continue to trade in Canada on the TSX under the symbol FTRP, and until the NASDAQ listing, in the U.S. on the OTCQX under the symbol FTRPF.

Concurrent with the NASDAQ listing, Field Trip’s shares will cease to be quoted on the OTCQX.

The company expects to satisfy all NASDAQ requirements and will issue a statement once a trading date has been confirmed.

Joseph del Moral, Field Trip’s CEO, commented,

“The anticipated listing of our stock on the NASDAQ is a key milestone in our evolution as a publicly-traded company. We believe this anticipated listing will improve liquidity by enabling more investors to participate in our growth and ultimately enhance long-term shareholder value. This is a critical time for us to increase our visibility in the marketplace, as we continue our work building a world-class and disruptive company at the forefront of the psychedelics industry.”

Mujeeb Jafferi, Field Trip’s COO, added,

“Psychedelics are experiencing a once-in-a-lifetime renaissance, as evidenced by the increasing support the industry is garnering from scientists, regulators and investors alike. We are proud to have established a leadership position in the industry at this exciting time and remain laser-focused on our drug development program advancing work on FT-104, our next-generation psychedelic molecule, and the continued rollout of our Field Trip Health clinics business, which is bringing much-needed psychedelic therapies to those in need.”

Field Trip is focused on the development and delivery of psychedelic therapies.

Field Trip Health (FTRP) is unchanged at $7.43 per share as of 11:30 am ET.

More From The Market Herald

" Leveljump Healthcare (TSXV:JUMP) provides Telehospital purchase update

Leveljump Healthcare (JUMP) has provided the following update on its pending acquisition of Telehospital Corp.
Reliq Health Technologies - CEO Dr. Lisa Crossley

" Reliq Health Technologies (TSXV:RHT) commences clinical trials and announces new contracts

Reliq Health Technologies (RHT) announced that its iUGO Care platform will go live in two clinical trials this month involving over 1,000 patients.

" Defence Therapeutics (CSE:DTC) reports that AccuVAC-PTE7 vaccine provides protection from cervical cancer

Defence Therapeutics (DTC) has announced the development of a dual-acting Accum-linked protein vaccine, AccuVAC-PTE7.

" Rubicon Organics Inc. (TSXV:ROMJ) obtains key certification for international export

Rubicon Organics’ (ROMJ) Delta Facility has received CUMCS Equivalency IMC-G.A.P. certification.